Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2020-09-18 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Share Capital Increase - 18 September 2020 - EN.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'share capital increase arising from subscription right exercises' and details the issuance of new ordinary shares and the resulting change in total share capital and voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific corporate action related to equity.
2020-09-18 English
Share Capital Increase - 18 September 2020 - NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated September 18, 2020, announcing a capital increase ('kapitaalverhoging') resulting from the exercise of subscription rights ('uitoefening van inschrijvingsrechten'). It details the number of new shares issued, the total capital raised, and updates the total number of voting rights and issued shares as required by Belgian transparency legislation. This content directly relates to changes in the company's capital structure and fundraising activities. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2020-09-18 Dutch
Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
Earnings Release Classification · 95% confidence The document is a press release dated September 11, 2020, announcing the topline results of a Phase 2a clinical study (NOVESA) for a drug candidate (ziritaxestat) in patients with systemic sclerosis. It details primary endpoint achievement (mRSS score change), safety data, and future plans, concluding with standard 'About' sections and forward-looking statements. This format—an immediate announcement of key clinical trial results—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/pipeline news. Since it focuses purely on clinical trial results and not comprehensive quarterly financials, it is best classified as an Earnings Release (ER) which often includes pipeline updates, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure and focus on reporting results, ER is the most appropriate fit among the specific options, as it serves as the initial public disclosure of performance metrics for a specific period/trial milestone. It is not a full Annual Report (10-K), Interim Report (IR), or a simple announcement of a report publication (RPA). Q3 2020
2020-09-11 English
Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
Earnings Release Classification · 95% confidence The document reports positive topline results from a Phase 2a clinical trial (NOVESA) for an investigational drug (ziritaxestat) in systemic sclerosis patients. It includes specific efficacy data (mRSS change), safety information, patient demographics, and quotes from the Chief Medical Officer. This content structure—announcing trial results and key data points immediately—is characteristic of an Earnings Release (ER) or a specific clinical trial update announcement. Since it focuses purely on the results of a specific period/trial and is not a comprehensive annual report (10-K) or a detailed management discussion (MDA), the most appropriate classification is Earnings Release (ER), as these announcements often coincide with reporting periods or serve as major operational updates. It is not an RPA because it contains the substantive results, not just an announcement that a report is attached. It is not an IR (Interim Report) because it is a press release focused on a single trial outcome, not a comprehensive financial filing for a fiscal period. Q3 2020
2020-09-11 English
6-K Filing
Regulatory Filings
2020-09-11 English
Galapagos presenteert nieuwe inzichten in IPF en gerelateerde klinische ontwikkelingen op het European Respiratory Society Congress
Investor Presentation Classification · 92% confidence The document is an announcement by Galapagos NV regarding its participation and presentations at the European Respiratory Society (ERS) Congress 2020. It details posters and symposia related to Idiopathic Pulmonary Fibrosis (IPF) research, including clinical trial data (PINTA Phase 2 trial) and patient insights. This type of communication, which announces upcoming scientific presentations, data releases, or participation in industry conferences, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or often falls under a general Investor Relations/Corporate Update category. Since the document is an announcement *about* presenting data and hosting symposia at a medical congress, and it contains forward-looking statements and contact information typical of investor communications, it aligns best with an Investor Presentation (IP) or a general corporate update. Given the options, 'Investor Presentation' (IP) is the most fitting category for material intended to convey scientific and strategic updates to the investment community, even if it's an announcement *of* presentations rather than the presentation slides themselves. It is not a formal regulatory filing (10-K, AR, ER, IR), nor is it a management change (MANG) or dividend notice (DIV). It is a proactive communication of scientific progress to investors.
2020-08-26 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.